RecruitingPhase 4NCT05139238

Postpartum Hypertension Study

Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)


Sponsor

Columbia University

Enrollment

104 participants

Start Date

Jul 4, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess which blood pressure medication (intravenous labetalol or oral nifedipine) works better in treating severely elevated blood pressure in women who have just delivered a baby.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study compares two blood pressure medications to find the safest and most effective way to treat very high blood pressure (severe-range hypertension) in women who have recently given birth (within 6 weeks postpartum). **You may be eligible if...** - You have recently given birth (up to 6 weeks postpartum) - Your blood pressure is severely elevated (systolic ≥160 or diastolic ≥110 mmHg) - You have a prior diagnosis of chronic hypertension or a hypertensive disorder of pregnancy (such as preeclampsia) **You may NOT be eligible if...** - You received either of the study medications in the past 24 hours - You have a known heart conduction problem (AV block) or moderate-to-severe asthma - You have another contraindication to the study medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLabetalol

Intravenous labetalol, a short acting ant-hypertensive

DRUGNifedipine

Oral nifedipine, a short acting ant-hypertensive


Locations(1)

Columbia University Irving Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05139238


Related Trials